Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive Article from MarketBeat Media
The Cannabis Sector's Billion-Dollar Tax CutAuthored by Jeffrey Neal Johnson. Originally Published: 4/23/2026. 
Key Points
- A major administrative policy shift is normalizing the tax structure for the cannabis industry, directly enhancing the financial standing of licensed operators.
- The largest multi-state operators are now positioned to leverage their significant revenues to generate substantial free cash flow for growth and expansion.
- This financial normalization shifts the investment focus from speculative policy hopes toward the tangible business fundamentals of established market leaders.
- Special Report: Elon’s “Hidden” Company
On the heels of the executive order to fast-track research into psychedelic drugs, a second major federal policy shift on April 23, 2026, is sending waves through the cannabis sector. But the real catalyst is widely misunderstood on Wall Street. The administration’s decision to reclassify state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act is not the same as federal legalization. Instead, the story is a surgical change buried in the U.S. tax code that could unlock billions in value for a select group of companies. For investors, this move rewrites the industry's rulebook—shifting it from speculative hope to a focus on tangible cash flow—and creates a clear new playbook for identifying potential profitability in the cannabis market. How the Death of 280E Changes Everything
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
For more than a decade, U.S. cannabis companies have been uniquely penalized by Internal Revenue Code Section 280E. Originally designed in the 1980s to prevent illegal drug traffickers from claiming tax deductions, 280E was applied to state-legal cannabis businesses. Put simply, licensed companies could not deduct ordinary and necessary business expenses from taxable income. Imagine a normal retail business being prohibited from deducting rent, payroll, or marketing. That forced cannabis operators to pay taxes on gross profits rather than net income, producing effective tax rates that often exceeded 70%. The administrative move to Schedule III effectively nullifies this rule for licensed medical operators. That change allows them to be taxed more like other businesses, reducing their effective tax rates toward the standard corporate rate of roughly 21%. For stock valuations, the impact is direct and powerful. The policy functions like a massive, non-dilutive infusion of cash onto company balance sheets. It is poised to improve net income, boost earnings per share (EPS), and give management teams hundreds of millions of dollars in new capital to fund growth, pay down debt, or return value to shareholders instead of sending it to the IRS. The New Kings of Cannabis Cash FlowDespite sector-wide excitement, this fiscal windfall will not lift all boats equally. While the transition to Schedule III is a broad administrative shift, the most substantial financial advantage—meaningful, non-dilutive liquidity—is being captured primarily by the leading U.S. Multi-State Operators (MSOs) with dominant revenue streams and robust operational infrastructures. The Profitability KingGreen Thumb Industries (OTCMKTS: GTBIF) stands out as a potential gold standard. It was the only major MSO to consistently generate positive net income even under the full weight of the 280E tax burden, reporting trailing net income of $114.15 million. With a reasonable price-to-earnings ratio (P/E) of about 15 before the change, Green Thumb’s profitability is set to expand meaningfully. That additional cash could be deployed to market its consumer brands—such as Rythm and Dogwalkers—and potentially accelerate market-share gains in key states. The Scale and Shareholder-Return PlayWith over $1.27 billion in annual sales, Curaleaf (OTCMKTS: CURLF) has the scale to see some of the largest absolute tax savings in the industry. Importantly, the company signaled confidence by launching an $83 million share buyback program. A buyback is a classic move for a mature company with excess cash. The timing—announced days before the policy shift—may be read as management preparing to return capital as the cash-drain from 280E is alleviated. That posture could attract value-oriented investors seeking dividend- and buyback-driven returns. The High-Leverage and Strategic Plays: Trulieve, Verano, and Cresco LabsOther MSOs look positioned to deploy tax savings into aggressive growth. Trulieve Cannabis (OTCMKTS: TCNNF), with dominant market share in Florida and strong political relationships, may use the additional cash to fortify its position ahead of any adult-use legalization ballot measures in the state. Meanwhile, Cresco Labs (OTCMKTS: CRLBF), which recently secured a medical license in the large Texas market, and Verano Holdings (OTCMKTS: VRNOF), which streamlined its structure by redomiciling to Nevada, now have more capital flexibility to fund expansion without taking on as much debt or diluting shareholders. The Tilray Contrast: Know What You OwnWhen cannabis is in the headlines, many investors naturally gravitate to familiar NASDAQ names like Tilray Brands, Inc. (NASDAQ: TLRY), assuming over-the-counter listings (OTCMKTS) are too risky. Tilray is one of the most liquid and widely held stocks in the sector, making it a common choice for traders seeking exposure to industry sentiment. However, Tilray’s business model differs materially from U.S. MSOs. Its operations are focused on the Canadian adult-use market, international medical markets in Europe, and a growing U.S. presence centered on craft beverage brands like SweetWater Brewing. Tilray is not a direct U.S. plant-touching operator and therefore was not subject to the punitive U.S. 280E tax. As a result, it does not receive the same direct financial uplift from this specific catalyst. For many investors, Tilray will be a sympathy trade rather than a primary beneficiary of the Schedule III reclassification. The Green Wave: A New Era for Cannabis ProfitsThe move to Schedule III is a partial but potentially transformative win. It does not legalize cannabis at the federal level, enable interstate commerce, or automatically clear the path for uplisting to major U.S. exchanges like the NASDAQ—those remain significant hurdles investors should track. But by normalizing tax treatment, the change gives the strongest U.S. operators the ability to build durable financial positions. The urgent need for federal banking reform remains, but it is less critical now that top MSOs can generate internal cash flow to fund operations and expansion. The investment playbook has shifted. Attention should move from speculating on broad policy reform to analyzing the fundamentals of U.S. MSOs that can convert large tax savings into sustainable earnings. While the industry has not received a full legal all-clear, it has received an official financial one. Investors interested in the space may want to add leading U.S. MSOs to their watchlists and monitor upcoming quarterly earnings reports for management’s first formal guidance in this post-280E environment. |
Post a Comment
0Comments